The test kit Vitrotest® Diphtheria-IgG is an enzyme linked immunosorbent assay (ELISA) for the quantitative determination of IgG class antibodies to diphtheria toxoid in human serum or plasma.
Determination of IgG antibodies to diphtheria toxoid in the test kit Vitrotest® Diphtheria-IgG is based on a solid phase, indirect ELISA.
○ ТК027 - 96 tests
- Solid phase: breakable microplate ELISA is coated with diphtheria toxoid.
- Conjugate: a monoclonal antibodies to human IgG conjugated to horseradish peroxidase.
- Chromogen: ready to use TMB solution.
- Volume of sample for analysis: 10 μl.
- Assay time: 1h 45 min.
Diphtheria is an infectious disease that primarily affects children. The causative agent of diphtheria Corynebacterium diphtheriae enters the human body, primarily infecting the throat and upper respiratory tract, and produces a toxin that can affect other organs. The disease is characterized by an acute onset, with the main symptoms being a sore throat, fever, and swollen glands in the neck. In severe cases, the bacteria produce a toxin that causes a thick gray or white film to form on the back of the throat.
The most important virulent factor of C. diphtheriae is the diphtheria toxin (exotoxin), which is secreted by the bacteria, enters the bloodstream, and damages the myocardium, kidneys, and central nervous system. Damage to the heart muscle can lead to arrhythmias, and nerve inflammation can cause paralysis.
Vaccination against diphtheria is a highly effective means of preventing the disease. According to WHO recommendations, all children worldwide should be vaccinated against diphtheria. The primary vaccination with diphtheria toxoid, consisting of three doses of the vaccine, should be administered to infants at the ages of 2, 4, and 6 months (with at least 4-week intervals between vaccinations). This should be followed by three booster immunizations with combined vaccines at the ages of 1-2, 4-7, and 9-15 years. At any age, those who are unvaccinated or incompletely vaccinated against diphtheria should receive the necessary doses to complete the vaccination series.
After the 3-dose primary series of the toxoid-containing vaccine, 94-100% of children show diphtheria antitoxin levels > 0.01 IU/ml, but booster doses of the vaccine are necessary to ensure long-term protection. Quantitative enzyme-linked immunosorbent assay (ELISA) for the determination of IgG antibodies to diphtheria toxoid is widely used to assess the level of protective immunity.
